Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 3-22 (IGHD3-22) is a member of the diversity (D) gene segment family located within the immunoglobulin heavy chain (IGH) gene locus on chromosome 14[6]. IGHD3-22 contributes to the diversity of the complementarity determining region 3 (CDR3) of immunoglobulin heavy chains, which is the central region responsible for the antigen binding specificity and diversity of antibodies[2][3][6]. During B cell development, IGHD3-22 can be incorporated into the V(D)J recombination process that forms unique B cell receptors and antibodies[2][4]. This genomic segment is essential for the adaptive immune response, supporting the generation of diverse antibody repertoires. There is no evidence that IGHD3-22 is itself a therapeutic target, nor is it a receptor or an enzyme; it is a genetic component that contributes to immune system variability. Changes in usage of particular IGHD genes—including IGHD3-22—may be observed in certain diseases such as some B cell leukemias, indicating potential research interest but not direct therapeutic targeting[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy diversity 3-22 (IGHD3-22).